CMS-Na was safely administered to healthy volunteers but resulted in transient increase of urinary N-acetyl-β-D-glucosaminidase (NAG) and protein. Based on this study, the highest recommended dose of CMS-Na had sufficient bacteriostatic effect.
In healthy Japanese subjects, no safety concerns were found following repeat dosing of FF and VI or single dosing of FF, VI and FF/VI. Systemic exposure to FF and VI increased in a dose-dependent manner. Serum cortisol level was suppressed by 97% after 7 days repeat administration of FF at a dose of 800 μg. Heart rate with a single dose of VI 50 μg was higher than that of placebo, though not to a clinically significant extent.
The pharmacokinetics and pharmacodynamics of eltrombopag, a thrombopoietin receptor agonist developed for idiopathic thrombocytopenic purpura, were investigated in healthy Japanese adult males after single and repeat doses of eltrombopag in two clinical studies. In the first study, subjects received a single oral dose of eltrombopag tablets at 30, 50, 75 and 100 mg and placebo in the fasted state. In the second study, each subject received single and once daily for 10 days repeat doses of eltrombopag(25, 50 or 75 mg)or placebo tablets. Plasma eltrombopag concentrations and platelet counts were measured in both studies. AUC and Cmax were proportional to dose within the range of 30-100 mg. / The AUC0−24 values after repeat doses of eltrombopag 25, 50 and 75 mg were 56, 130 and 161 mg・hr/mL, respectively, increasing nearly proportionally to the dose increase. The plasma concentration reached steady state in approximately 7 days after starting the repeat dose, and the change in pharmacokinetics caused by repeat dose was small. The AUC values obtained after single and repeat dose in Japanese subjects were nearly twofold higher than those previously reported in non-Japanese subjects(predominantly white). No significant changes in platelet count were observed after single oral doses up to 100 mg of eltrombopag. When 25, 50 and 75 mg were administered once daily for 10 days, the maximum increase in platelet count from the baseline was 54%, 72% and 90%, respectively, showing a dose-dependent increase. These increases were higher as compared with the previously reported increases in platelet count observed after 30, 50 and 75 mg were administered once daily for 10 days to non-Japanese healthy adults. The increase in platelet count from baseline became higher with increasing AUC in Japanese healthy adults. These results suggest that the difference in platelet count increase between Japanese and non-Japanese is probably associated with the observed inter-ethnic difference in AUC. Eltrombopag might be used at a lower dosage in Japanese than in non-Japanese to attain similar degrees of platelet count increase.
Single and 5-day BID repeat dosing of 600 mg were safely administered in Japanese healthy subjects. The pharmacokinetic profile of zanamivir after intravenous administration was consistent with previously reported findings in non-Japanese subjects.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.